Shanghai Leadingtac Pharmaceutical Co. Ltd. has synthesized proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase-binding moiety covalently linked to a GTPase KRAS (G12D mutant)-targeting moiety via a linker reported to be useful for the treatment of cancer.

Shanghai Innoxtal Therapeutics Co. Ltd. has disclosed sodium channel protein type 10 subunit α (SCN10A; Nav1.8) blockers reported to be useful for the treatment of pain, arrhythmia and urinary incontinence.

Inje University has described 3-phosphoinositide-dependent protein kinase 1 (PDPK1) inhibitors reported to be useful for the treatment of cancer and autoimmune diseases.

Keythera (Suzhou) Pharmaceuticals Co. Ltd. has divulged mas-related G-protein coupled receptor member X2 (MRGPRX2) antagonists reported to be useful for the treatment of urticaria, allergy, asthma, pruritus, arthritis, nasal polyps, dermatitis and irritable bowel syndrome, among others.

Eluciderm Inc. has identified compounds acting as inhibitors of Wnt signaling and/or poly(ADP-ribose) polymerase tankyrase-2 (TNKS2; PARP5B) and/or poly(ADP-ribose) polymerase 1 (PARP-1; ARTD1) and/or PARP-2 (ARTD2) reported to be useful for the treatment of cancer, acne, rosacea, psoriasis and scleroderma.

Eli Lilly and Co. has synthesized glucagon receptor (GCGR) agonists reported to be useful for the treatment of type 2 diabetes and obesity.

Kolm Therapeutics Inc. has disclosed heterobifunctional compounds comprising a disease-dependent protein binding moiety (particularly, CREB-binding protein [CREBBP; CBP] or histone acetyltransferase p300 [EP300]) covalently linked to a disease protein (particularly, androgen receptor) through a linker.

Sage Therapeutics Inc. has described sterol derivatives acting as glutamate receptor ionotropic, NMDA 2A (GRIN2A; GluN2A) negative allosteric modulators reported to be useful for the treatment of neurological disorders.

Shanghai Leadingtac Pharmaceutical Co. Ltd. has divulged proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase-binding moiety covalently linked to a pan-KRAS-targeting moiety through a linker.

Petra Pharma Corp. has identified phosphatidylinositol 3-kinase α (PI3Kα) E545K and H1047R mutant inhibitors reported to be useful for the treatment of cancer, congenital lipomatous overgrowth, vascular malformations, epidermal naevi and skeletal abnormalities and PIK3CA-related overgrowth spectrum (PROS).